Meqsel in made by Novartis in Europe. It is the same as Mekinist but you can save 70% at insulinhub.
Information about Meqsel (Trametinib)
Meqsel is an oral medication classified as a MEK inhibitor, specifically targeting the MAPK/ERK signaling pathway, which is crucial in the proliferation and survival of certain cancer cells. It is used in the treatment of specific types of cancer that have specific genetic mutations.
Product Highlights
Meqsel is primarily indicated for:
Management of unresectable or metastatic melanoma with a BRAF V600E or V600K mutation.
Treatment of non-small cell lung cancer (NSCLC) with a BRAF V600E mutation.
Treatment of other cancers associated with BRAF mutations.
Key Ingredient
Trametinib
Key Benefits
Specifically targets cancers with BRAF mutations, providing a tailored treatment approach.
May improve progression-free survival rates in patients with certain types of melanoma and other malignancies.
Possibly fewer side effects than traditional chemotherapy.
Direction of Use
Take Meqsel exactly as prescribed by your healthcare provider.
Swallow the tablet whole, with or without food; do not crush or chew.
Adhere to regular follow-up appointments for monitoring response and side effects.
Recommended MEKINIST Dose Level Reductions
Dose Level
MEKINIST Dose
Starting Dose
2 mg once daily
1st Dose Reduction
1.5 mg once daily
2nd Dose Reduction
1 mg once daily
Safety Concerns
Common side effects may include skin rash, diarrhea, nausea, fatigue, and peripheral edema.
There is a risk of serious skin reactions, blood clots, and liver toxicity.
Regular blood tests may be required to monitor liver function and other parameters.
Avoid Meqsel (Trametinib) If
You have a known hypersensitivity to trametinib or any of its components.
You are pregnant or breastfeeding, as it may pose risks to the fetus or infant.
You have severe liver impairment or certain pre-existing health conditions that may be exacerbated by treatment.
You are taking medications that could interact negatively with Meqsel.
